Drug Profile


Alternative Names: Beclomethasone dipropionate/formoterol - Chiesi; Beclomethasone/formoterol; CHF 1535 35/4 NEXTHALER®; CHF-1535; Combair; Formodual; Formoterol/beclometasone; Formoterol/beclomethasone dipropionate; Fostair; Fostair NEXThaler; Foster; Foster Nexthaler; Foster Spray; Fostex; Fostex NEXThaler; Innovair; Innovair NEXThaler; Inuvair; Inuver; Inuxair; Kantos; Kantos Master; Kantos NEXThaler

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics; Corticosteroids; Ethanolamines; Pregnadienetriols; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Jun 2017 Chiesi Farmaceutici completes a phase II trial for Asthma (In children, New delivery system) in Denmark (Inhalation) (NCT02787967) (EudraCT2015-005152-10)
  • 25 Jan 2017 The US FDA grants six months of paediatric exclusivity to beclometasone/formoterol for the treatment of Asthma in USA
  • 20 Dec 2016 Chiesi initiates enrolment in a phase II trial for Asthma in United Kingdom (EudraCT2016-003672-47)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top